De Kleijn DPV - Search Results

1

Innate immunity as a target for acute cardioprotection.

Zuurbier CJ, Abbate A, Cabrera-Fuentes HA, Cohen MV, Collino M, De Kleijn DPV, Downey JM, Pagliaro P, Preissner KT, Takahashi M, Davidson SM. Zuurbier CJ, et al. Among authors: de kleijn dpv. Cardiovasc Res. 2019 Jun 1;115(7):1131-1142. doi: 10.1093/cvr/cvy304. Cardiovasc Res. 2019. PMID: 30576455 Free PMC article. Review.

2

Bridging innate immunity and myocardial ischemia/reperfusion injury: the search for therapeutic targets.

Arslan F, de Kleijn DP, Timmers L, Doevendans PA, Pasterkamp G. Arslan F, et al. Curr Pharm Des. 2008;14(12):1205-16. doi: 10.2174/138161208784246090. Curr Pharm Des. 2008. PMID: 18473868 Review.

3

Targeted deletion of the inhibitory NF-kappaB p50 subunit in bone marrow-derived cells improves collateral growth after arterial occlusion.

de Groot D, Haverslag RT, Pasterkamp G, de Kleijn DP, Hoefer IE. de Groot D, et al. Cardiovasc Res. 2010 Oct 1;88(1):179-85. doi: 10.1093/cvr/cvq150. Epub 2010 May 21. Cardiovasc Res. 2010. PMID: 20495189

4

Innate immune signaling in cardiac ischemia.

Arslan F, de Kleijn DP, Pasterkamp G. Arslan F, et al. Nat Rev Cardiol. 2011 May;8(5):292-300. doi: 10.1038/nrcardio.2011.38. Epub 2011 Mar 29. Nat Rev Cardiol. 2011. PMID: 21448140 Review.

5

The innate immune response in reperfused myocardium.

Timmers L, Pasterkamp G, de Hoog VC, Arslan F, Appelman Y, de Kleijn DP. Timmers L, et al. Cardiovasc Res. 2012 May 1;94(2):276-83. doi: 10.1093/cvr/cvs018. Epub 2012 Jan 20. Cardiovasc Res. 2012. PMID: 22266751 Review.

6

Treatment with OPN-305, a humanized anti-Toll-Like receptor-2 antibody, reduces myocardial ischemia/reperfusion injury in pigs.

Arslan F, Houtgraaf JH, Keogh B, Kazemi K, de Jong R, McCormack WJ, O'Neill LA, McGuirk P, Timmers L, Smeets MB, Akeroyd L, Reilly M, Pasterkamp G, de Kleijn DP. Arslan F, et al. Circ Cardiovasc Interv. 2012 Apr;5(2):279-87. doi: 10.1161/CIRCINTERVENTIONS.111.967596. Epub 2012 Feb 21. Circ Cardiovasc Interv. 2012. PMID: 22354933

7

Targeting cell death in the reperfused heart: pharmacological approaches for cardioprotection.

Oerlemans MI, Koudstaal S, Chamuleau SA, de Kleijn DP, Doevendans PA, Sluijter JP. Oerlemans MI, et al. Int J Cardiol. 2013 May 25;165(3):410-22. doi: 10.1016/j.ijcard.2012.03.055. Epub 2012 Mar 28. Int J Cardiol. 2013. PMID: 22459400 Review.

8

Leucocyte expression of complement C5a receptors exacerbates infarct size after myocardial reperfusion injury.

De Hoog VC, Timmers L, Van Duijvenvoorde A, De Jager SC, Van Middelaar BJ, Smeets MB, Woodruff TM, Doevendans PA, Pasterkamp G, Hack CE, De Kleijn DP. De Hoog VC, et al. Cardiovasc Res. 2014 Sep 1;103(4):521-9. doi: 10.1093/cvr/cvu153. Epub 2014 Jun 15. Cardiovasc Res. 2014. PMID: 24935433

9

BLT1 antagonist LSN2792613 reduces infarct size in a mouse model of myocardial ischaemia-reperfusion injury.

de Hoog VC, Bovens SM, de Jager SC, van Middelaar BJ, van Duijvenvoorde A, Doevendans PA, Pasterkamp G, de Kleijn DP, Timmers L. de Hoog VC, et al. Cardiovasc Res. 2015 Dec 1;108(3):367-76. doi: 10.1093/cvr/cvv224. Epub 2015 Oct 8. Cardiovasc Res. 2015. PMID: 26449403

10

Toll-like receptor 7 deficiency promotes survival and reduces adverse left ventricular remodelling after myocardial infarction.

de Kleijn DPV, Chong SY, Wang X, Yatim SMJM, Fairhurst AM, Vernooij F, Zharkova O, Chan MY, Foo RSY, Timmers L, Lam CSP, Wang JW. de Kleijn DPV, et al. Cardiovasc Res. 2019 Oct 1;115(12):1791-1803. doi: 10.1093/cvr/cvz057. Cardiovasc Res. 2019. PMID: 30830156

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

279 results

Search Page